

Media Backgrounder:

Janssen in Diabetes

Introduction

Diabetes, especially type 2 diabetes, obesity and heart disease are increasing medical problems in the 21st century. Poor diets and modern lifestyles in a growing number of regions across the world are contributing to these problems, which are becoming critical worldwide health issues. In the EMEA region the demographic evolution towards an ageing population is expected to lead to increased numbers of diabetes and heart disease.

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, in fields such as oncology, immunology, neuroscience, infectious disease, cardiovascular and metabolic diseases. Driven by its commitment to patients, the company develops innovative products, services and healthcare solutions to help people throughout the world.

Janssen in Diabetes – Unmet need and the company’s commitment

Despite the availability of many treatments for type 2 diabetes, approximately half of patients have not reached treatment goals at any given time and more treatment options are needed which provide strong, sustained efficacy in lowering excess blood glucose which work independent of insulin.^{1,2}

To respond to this unmet need, Janssen developed INVOKANA® (canagliflozin), an oral, once-daily sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes. SGLT2 inhibitors work by excreting excess glucose via the urine.³

The development of canagliflozin included a comprehensive global Phase 3 clinical trial programme, which was submitted as part of the licencing process. This is one of the largest late-stage development programmes for a medicinal product for the treatment of type 2 diabetes conducted to date.

Many patients with type 2 diabetes often fail to maintain glucose control over the long term and go on to take a combination of several glucose lowering agents. Janssen has also developed VOKANAMET®, a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride, a commonly used glucose lowering agent, in a single tablet.

Our reach and investment

The Janssen Pharmaceutical Companies of Johnson & Johnson are active across five continents, and in more than 100 countries within Europe, the Middle East & Africa (EMEA).

Annually, Janssen invests around \$1.5 billion in research and development in the EMEA region with eight research and development centres and 10 manufacturing sites for worldwide distribution of medicines and vaccines.

Johnson & Johnson Family of Diabetes Companies worldwide

The management of diabetes and its associated complications is at the heart of all the work of the Johnson & Johnson Family of Diabetes Companies, envisioning a world without limits for people with diabetes.

In addition to Janssen’s pharmaceutical product, the portfolio of the Johnson & Johnson Family of Diabetes Companies includes devices (such as insulin pumps), diagnostics (such as glucose meters), nutritional products (such as sugar alternatives), and services, to help patients to better manage their diabetes.

Media Backgrounder:

Janssen in Diabetes

Other Johnson & Johnson Family of Diabetes Companies include:



Lifescan

LifeScan is a world leading blood glucose monitoring system company, with products designed to empower patients and healthcare professionals to better manage diabetes. Founded in 1981 LifeScan became part of the Johnson & Johnson Family of Companies in 1986.



Animas

Animas develops and makes insulin pumps and medical devices which are designed to give type 2 diabetes patients day-to-day glycaemic control.



Ethicon Endo-Surgery

Ethicon Endo-Surgery, is the world's leading provider of innovative solutions for minimally-invasive (laparoscopic) and open surgical procedures, including bariatric surgery which may contribute to reduce obesity-related co-morbidities amongst people with type 2 diabetes.



McNeil Nutritionals

McNeil Nutritionals is a global marketer of innovative nutritional products that develops and produces nutritional products to help people actively manage their health through dietary approaches, healthy food options, such as sugar alternatives, or products proven to reduce cholesterol as part of a healthy, balanced diet and lifestyle.



Cordis

For more than 50 years, Cordis Corporation has been developing and manufacturing products including catheters and stents - to treat patients with cardiovascular disease, with a focus on coronary and peripheral vascular diseases which can be caused by diabetes.



Johnson & Johnson Diabetes Institute

The Johnson & Johnson Diabetes Institute's mission is to improve the paradigm of diabetes care – transforming the intent from managing diabetes to mastering diabetes through the provision of advanced training in diabetes care for healthcare professionals.

The institute is a collaborative learning environment, comprised of an online community and global facilities. Healthcare professionals learn from the faculty and from each other, achieving the vision of the Institute to transform diabetes care.

More information on Janssen can be found at:
www.janssen-emea.com

References

- 1 Bailey CJ. *Renal glucose reabsorption inhibitors to treat diabetes*. Trends Pharmacol Sci. 2011;32(2);63-71.
- 2 Nau DP. *Recommendations for Improving Adherence to Type 2 Diabetes Mellitus Therapy – Focus on Optimising Oral and Non-Insulin Therapies*. Am J Manag. Care. 2012;18:549-554.
- 3 Freeman J.S. *Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors*. Postgrad Med. 2013 May;125(3):214-26. doi: 10.3810/pgm.2013.05.2672.